Cell penetrating elastin-like polypeptides for therapeutic peptide delivery

Advanced Drug Delivery Reviews

Volumn 62, Issue 15, 2010, Pages 1486-1496

  Bidwell, Gene L ^a   Raucher, Drazen ^a  

^a UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

Author keywords

C Myc; Cell penetrating peptide; Elastin like polypeptide; P21; Therapeutic peptide; Thermal targeting

Indexed keywords

C-MYC; CELL PENETRATING PEPTIDE; ELASTIN-LIKE POLYPEPTIDES; P21; THERAPEUTIC PEPTIDES; THERMAL TARGETING;

BIOMIMETICS; BRAIN MODELS; DRUG INTERACTIONS; GLYCOPROTEINS; POLYPEPTIDES; TUMORS;

PEPTIDES;

CAMPTOTHECIN; CELL PENETRATING PEPTIDE; CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR; DOXORUBICIN; ELASTIN; ETOPOSIDE; MYC PROTEIN; ORNITHINE DECARBOXYLASE; POLYPEPTIDE; POLYPEPTIDE H1; PROTEIN P21; RHODAMINE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CELL PROLIFERATION; CELL STRUCTURE; CELL SURFACE; CELL VIABILITY; CELLULAR DISTRIBUTION; DRUG DELIVERY SYSTEM; DRUG POTENCY; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; HELA CELL; HUMAN; HYPERTHERMIA; IN VITRO STUDY; INTERNALIZATION; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW;

ANIMALS; CELL-PENETRATING PEPTIDES; DRUG DELIVERY SYSTEMS; ELASTIN; HUMANS; PEPTIDES;

EID: 78649846843     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2010.05.003     Document Type: Review

References (78)

1. Greish K. Enhanced permeability and retention of macromolecular drugs in solid tumors: a royal gate for targeted anticancer nanomedicines. J. Drug Target. 2007, 15(7-8):457-464.
2. Iyer A.K., Khaled G., Fang J., Maeda H. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov. Today 2006, 11(17-18):812-818.
3. Maeda H., Bharate G.Y., Daruwalla J. Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. Eur. J. Pharm. Biopharm. 2009, 71(3):409-419.
4. Talelli M., Rijcken C.J., van Nostrum C.F., Storm G., Hennink W.E. Micelles based on HPMA copolymers. Adv. Drug Deliv. Rev. 2009, 62(2):231-239.
5. Matsumura Y. Poly (amino acid) micelle nanocarriers in preclinical and clinical studies. Adv. Drug Deliv. Rev. 2008, 60(8):899-914.
6. Vicent M.J., Duncan R. Polymer conjugates: nanosized medicines for treating cancer. Trends Biotechnol. 2006, 24(1):39-47.
7. Hu X., Jing X. Biodegradable amphiphilic polymer-drug conjugate micelles. Expert Opin. Drug Deliv. 2009, 6(10):1079-1090.
8. Khare P., Jain A., Gulbake A., Soni V., Jain N.K., Jain S.K. Bioconjugates: harnessing potential for effective therapeutics. Crit. Rev. Ther. Drug Carrier Syst. 2009, 26(2):119-155.
9. Urry D.W., Luan C.-H., Parker T.M., Gowda D.C., Prasad K.U., Reid M.C., Safavy A. Temperature of polypeptide inverse temperature transition depends on mean residue hydrophobicity. J. Am. Chem. Soc. 1991, 113:4346-4348.
10. Urry D.W., Trapane T.L., Prasad K.U. Phase-structure transitions of the elastin polypentapeptide-water system within the framework of composition-temperature studies. Biopolymers 1985, 24(12):2345-2356.
11. Urry D.W. Free energy transduction in polypeptides and proteins based on inverse temperature transitions. Prog. Biophys. Mol. Biol. 1992, 57(1):23-57.
12. Meyer D.E., Kong G.A., Dewhirst M.W., Zalutsky M.R., Chilkoti A. Targeting a genetically engineered elastin-like polypeptide to solid tumors by local hyperthermia. Cancer Res. 2001, 61(4):1548-1554.
13. Dreher M.R., Liu W., Michelich C.R., Dewhirst M.W., Chilkoti A. Thermal cycling enhances the accumulation of a temperature-sensitive biopolymer in solid tumors. Cancer Res. 2007, 67(9):4418-4424.
14. Liu W., Dreher M.R., Furgeson D.Y., Peixoto K.V., Yuan H., Zalutsky M.R., Chilkoti A. Tumor accumulation, degradation and pharmacokinetics of elastin-like polypeptides in nude mice. J. Control. Release 2006, 116(2):170-178.
15. Issels R.D. Regional hyperthermia combined with systemic chemotherapy of locally advanced sarcomas: preclinical aspects and clinical results. Recent Results Cancer Res. 1995, 138:81-90.
16. Feyerabend T., Steeves R., Wiedemann G.J., Richter E., Robins H.I. Rationale and clinical status of local hyperthermia, radiation, and chemotherapy in locally advanced malignancies. Anticancer Res. 1997, 17(4B):2895-2897.
17. van Vulpen M., Raaymakers B.W., de Leeuw A.A., van de Kamer J.B., van Moorselaar R.J., Hobbelink M.G., Battermann J.J., Lagendijk J.J. Prostate perfusion in patients with locally advanced prostate carcinoma treated with different hyperthermia techniques. J. Urol. 2002, 168(4 Pt 1):1597-1602.
18. Issels R.D. Regional hyperthermia in high-risk soft tissue sarcomas. Curr. Opin. Oncol. 2008, 20(4):438-443.
19. Falk M.H., Issels R.D. Hyperthermia in oncology. Int. J. Hyperthermia 2001, 17(1):1-18.
20. Dewhirst M.W., Prosnitz L., Thrall D., Prescott D., Clegg S., Charles C., MacFall J., Rosner G., Samulski T., Gillette E., LaRue S. Hyperthermic treatment of malignant diseases: current status and a view toward the future. Semin. Oncol. 1997, 24(6):616-625.
21. Takahashi I., Emi Y., Hasuda S., Kakeji Y., Maehara Y., Sugimachi K. Clinical application of hyperthermia combined with anticancer drugs for the treatment of solid tumors. Surgery 2002, 131(1 Suppl):S78-84.
22. Jain R.K. Transport of molecules, particles, and cells in solid tumors. Annu. Rev. Biomed. Eng. 1999, 1:241-263.
23. Jain R.K. Delivery of novel therapeutic agents in tumors: physiological barriers and strategies. J. Natl Cancer Inst. 1989, 81(8):570-576.
24. Jain R.K. Transport of molecules across tumor vasculature. Cancer Metastasis Rev. 1987, 6(4):559-593.
25. Nori A., Kopecek J. Intracellular targeting of polymer-bound drugs for cancer chemotherapy. Adv. Drug Deliv. Rev. 2005, 57(4):609-636.
26. Snyder E.L., Dowdy S.F. Cell penetrating peptides in drug delivery. Pharm. Res. 2004, 21(3):389-393.
27. Temsamani J., Vidal P. The use of cell-penetrating peptides for drug delivery. Drug Discov. Today 2004, 9(23):1012-1019.
28. Gupta B., Levchenko T.S., Torchilin V.P. Intracellular delivery of large molecules and small particles by cell-penetrating proteins and peptides. Adv. Drug Deliv. Rev. 2005, 57(4):637-651.
29. Heitz F., Morris M.C., Divita G. Twenty years of cell-penetrating peptides: from molecular mechanisms to therapeutics. Br. J. Pharmacol. 2009, 157(2):195-206.
30. Schwarze S.R., Ho A., Vocero-Akbani A., Dowdy S.F. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 1999, 285(5433):1569-1572.
31. Rousselle C., Clair P., Lefauconnier J.M., Kaczorek M., Scherrmann J.M., Temsamani J. New advances in the transport of doxorubicin through the blood-brain barrier by a peptide vector-mediated strategy. Mol. Pharmacol. 2000, 57(4):679-686.
32. Drin G., Rousselle C., Scherrmann J.M., Rees A.R., Temsamani J. Peptide delivery to the brain via adsorptive-mediated endocytosis: advances with SynB vectors. AAPS Pharm. Sci. 2002, 4(4):E26.
33. Adenot M., Merida P., Lahana R. Applications of a blood-brain barrier technology platform to predict CNS penetration of various chemotherapeutic agents. 2. Cationic peptide vectors for brain delivery. Chemotherapy 2007, 53(1):73-76.
34. Vives E., Schmidt J., Pelegrin A. Cell-penetrating and cell-targeting peptides in drug delivery. Biochim. Biophys. Acta 2008, 1786(2):126-138.
35. Bidwell G.L., Raucher D. Application of thermally responsive polypeptides directed against c-Myc transcriptional function for cancer therapy. Mol. Cancer Ther. 2005, 4(7):1076-1085.
36. Bidwell G.L., Davis A.N., Raucher D. Targeting a c-Myc inhibitory polypeptide to specific intracellular compartments using cell penetrating peptides. J. Control. Release 2009, 135(1):2-10.
37. Bidwell G.L., Fokt I., Priebe W., Raucher D. Development of elastin-like polypeptide for thermally targeted delivery of doxorubicin. Biochem. Pharmacol. 2007, 73(5):620-631.
38. Massodi I., Bidwell G.L., Raucher D. Evaluation of cell penetrating peptides fused to elastin-like polypeptide for drug delivery. J. Control. Release 2005, 108(2-3):396-408.
39. Bidwell G.L., Raucher D. Therapeutic peptides for cancer therapy. Part I-peptide inhibitors of signal transduction cascades. Expert Opin. Drug Deliv. 2009, 6(10):1033-1047.
40. Raucher D., Moktan S., Massodi I., Bidwell G.L. Therapeutic peptides for cancer therapy. Part II-Cell cycle inhibitory peptides and apoptosis-inducing peptides. Expert Opin. Drug Deliv. 2009, 6(10):1049-1064.
41. Lipka E., Crison J., Amidon G.L. Transmembrane transport of peptide type compounds: prospects for oral delivery. J. Control. Release 1996, 39(2-3):121-129.
42. Talmadge J.E. Pharmacodynamic aspects of peptide administration biological response modifiers. Adv. Drug Deliv. Rev. 1998, 33(3):241-252.
43. Jung T., Kamm W., Breitenbach A., Kaiserling E., Xiao J.X., Kissel T. Biodegradable nanoparticles for oral delivery of peptides: is there a role for polymers to affect mucosal uptake?. Eur. J. Pharm. Biopharm. 2000, 50(1):147-160.
44. Torchilin V.P., Levchenko T.S. TAT-liposomes: a novel intracellular drug carrier. Curr. Protein Pept. Sci. 2003, 4(2):133-140.
45. MacKay J.A., Chen M., McDaniel J.R., Liu W., Simnick A.J., Chilkoti A. Self-assembling chimeric polypeptide-doxorubicin conjugate nanoparticles that abolish tumours after a single injection. Nat. Mater. 2009, 8(12):993-999.
46. Dreher M.R., Raucher D., Balu N., Michael Colvin O., Ludeman S.M., Chilkoti A. Evaluation of an elastin-like polypeptide-doxorubicin conjugate for cancer therapy. J. Control. Release 2003, 91(1-2):31-43.
47. Bidwell G.L., Davis A.N., Fokt I., Priebe W., Raucher D. A thermally targeted elastin-like polypeptide-doxorubicin conjugate overcomes drug resistance. Investig. New Drugs 2007, 25(4):313-326.
48. Chen T.H., Bae Y., Furgeson D.Y. Intelligent biosynthetic nanobiomaterials (IBNs) for hyperthermic gene delivery. Pharm. Res. 2008, 25(3):683-691.
49. Massodi I., Thomas E., Raucher D. Application of thermally responsive elastin-like polypeptide fused to a lactoferrin-derived peptide for treatment of pancreatic cancer. Molecules 2009, 14(6):1999-2015.
50. Massodi I., Moktan S., Rawat A., Bidwell G.L., Raucher D. Inhibition of ovarian cancer cell proliferation by a cell cycle inhibitory peptide fused to a thermally responsive polypeptide carrier. Int. J. Cancer 2010, 126(2):533-544.
51. Shamji M.F., Chen J., Friedman A.H., Richardson W.J., Chilkoti A., Setton L.A. Synthesis and characterization of a thermally-responsive tumor necrosis factor antagonist. J. Control. Release 2008, 129(3):179-186.
52. Meyer D.E., Chilkoti A. Genetically encoded synthesis of protein-based polymers with precisely specified molecular weight and sequence by recursive directional ligation: examples from the elastin-like polypeptide system. Biomacromolecules 2002, 3(2):357-367.
53. Derossi D., Joliot A.H., Chassaing G., Prochiantz A. The third helix of the Antennapedia homeodomain translocates through biological membranes. J. Biol. Chem. 1994, 269(14):10444-10450.
54. Vives E., Brodin P., Lebleu B. A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J. Biol. Chem. 1997, 272(25):16010-16017.
55. Lin Y.Z., Yao S.Y., Veach R.A., Torgerson T.R., Hawiger J. Inhibition of nuclear translocation of transcription factor NF-kappa B by a synthetic peptide containing a cell membrane-permeable motif and nuclear localization sequence. J. Biol. Chem. 1995, 270(24):14255-14258.
56. Sadler K., Eom K.D., Yang J.L., Dimitrova Y., Tam J.P. Translocating proline-rich peptides from the antimicrobial peptide bactenecin 7. Biochemistry 2002, 41(48):14150-14157.
57. Richard J.P., Melikov K., Vives E., Ramos C., Verbeure B., Gait M.J., Chernomordik L.V., Lebleu B. Cell-penetrating peptides. A reevaluation of the mechanism of cellular uptake. J. Biol. Chem. 2003, 278(1):585-590.
58. Derossi D., Chassaing G., Prochiantz A. Trojan peptides: the penetratin system for intracellular delivery. Trends Cell. Biol. 1998, 8(2):84-87.
59. Vives E., Richard J.P., Rispal C., Lebleu B. TAT peptide internalization: seeking the mechanism of entry. Curr. Protein Pept. Sci. 2003, 4(2):125-132.
60. Edenhofer F. Protein transduction revisited: novel insights into the mechanism underlying intracellular delivery of proteins. Curr. Pharm. Des. 2008, 14(34):3628-3636.
61. Heuser J.E., Anderson R.G. Hypertonic media inhibit receptor-mediated endocytosis by blocking clathrin-coated pit formation. J. Cell. Biol. 1989, 108(2):389-400.
62. Thyberg J. Caveolae and cholesterol distribution in vascular smooth muscle cells of different phenotypes. J. Histochem. Cytochem. 2002, 50(2):185-195.
63. Pelengaris S., Khan M., Evan G. c-MYC: more than just a matter of life and death. Nat. Rev. Cancer 2002, 2(10):764-776.
64. Draeger L.J., Mullen G.P. Interaction of the bHLH-zip domain of c-Myc with H1-type peptides. Characterization of helicity in the H1 peptides by NMR. J. Biol. Chem. 1994, 269(3):1785-1793.
65. Giorello L., Clerico L., Pescarolo M.P., Vikhanskaya F., Salmona M., Colella G., Bruno S., Mancuso T., Bagnasco L., Russo P., Parodi S. Inhibition of cancer cell growth and c-Myc transcriptional activity by a c-Myc helix 1-type peptide fused to an internalization sequence. Cancer Res. 1998, 58(16):3654-3659.
66. Pescarolo M.P., Bagnasco L., Malacarne D., Melchiori A., Valente P., Millo E., Bruno S., Basso S., Parodi S. A retro-inverso peptide homologous to helix 1 of c-Myc is a potent and specific inhibitor of proliferation in different cellular systems. FASEB J. 2001, 15(1):31-33.
67. Bidwell G.L., Raucher D. Enhancing the antiproliferative effect of topoisomerase II inhibitors using a polypeptide inhibitor of c-Myc. Biochem. Pharmacol. 2006, 71(3):248-256.
68. Bakic M., Chan D., Freireich E.J., Marton L.J., Zwelling L.A. Effect of polyamine depletion by alpha-difluoromethylornithine or (2R, 5R)-6-heptyne-2, 5-diamine on drug-induced topoisomerase II-mediated DNA cleavage and cytotoxicity in human and murine leukemia cells. Cancer Res. 1987, 47(24 Pt 1):6437-6443.
69. Desiderio M.A., Bergamaschi D., Mascellani E., De Feudis P., Erba E., D'Incalci M. Treatment with inhibitors of polyamine biosynthesis, which selectively lower intracellular spermine, does not affect the activity of alkylating agents but antagonizes the cytotoxicity of DNA topoisomerase II inhibitors. Br. J. Cancer 1997, 75(7):1028-1034.
70. Feuerstein B.G., Pattabiraman N., Marton L.J. Spermine-DNA interactions: a theoretical study. Proc. Natl Acad. Sci. USA 1986, 83(16):5948-5952.
71. Hung D.T., Marton L.J., Deen D.F., Shafer R.H. Depletion of intracellular polyamines may alter DNA conformation in 9L rat brain tumor cells. Science 1983, 221(4608):368-370.
72. Warbrick E., Lane D.P., Glover D.M., Cox L.S. A small peptide inhibitor of DNA replication defines the site of interaction between the cyclin-dependent kinase inhibitor p21WAF1 and proliferating cell nuclear antigen. Curr. Biol. 1995, 5(3):275-282.
73. Chen I.T., Akamatsu M., Smith M.L., Lung F.D., Duba D., Roller P.P., Fornace A.J., O'Connor P.M. Characterization of p21Cip1/Waf1 peptide domains required for cyclin E/Cdk2 and PCNA interaction. Oncogene 1996, 12(3):595-607.
74. Pan Z.Q., Reardon J.T., Li L., Flores-Rozas H., Legerski R., Sancar A., Hurwitz J. Inhibition of nucleotide excision repair by the cyclin-dependent kinase inhibitor p21. J. Biol. Chem. 1995, 270(37):22008-22016.
75. Ball K.L., Lain S., Fahraeus R., Smythe C., Lane D.P. Cell-cycle arrest and inhibition of Cdk4 activity by small peptides based on the carboxy-terminal domain of p21WAF1. Curr. Biol. 1997, 7(1):71-80.
76. Cayrol C., Knibiehler M., Ducommun B. p21 binding to PCNA causes G1 and G2 cell cycle arrest in p53-deficient cells. Oncogene 1998, 16(3):311-320.
77. Mutoh M., Lung F.D., Long Y.Q., Roller P.P., Sikorski R.S., O'Connor P.M. A p21(Waf1/Cip1)carboxyl-terminal peptide exhibited cyclin-dependent kinase-inhibitory activity and cytotoxicity when introduced into human cells. Cancer Res. 1999, 59(14):3480-3488.
78. Mattock H., Lane D.P., Warbrick E. Inhibition of cell proliferation by the PCNA-binding region of p21 expressed as a GFP miniprotein. Exp. Cell Res. 2001, 265(2):234-241.